In the news

As lifespans grow longer, targeted medical technology can help people live better, healthier lives—with fewer pills.

Dr. Janar Sathananthan, president, Interventional Cardiology, discusses the FRACTURE IDE trial, which met its primary endpoints for the SEISMIQ™ 4CE Coronary IVL Catheter in severely calcified coronary disease. The result underscores Boston Scientific’s broader intravascular lithotripsy commercialization strategy and differentiated cardiology solutions.

Karen Carlson’s incontinence kept her housebound for years despite various failed treatments. The Axonics™ Sacral Neuromodulation Therapy helped relieve her symptoms, restoring her active life.

This sponsored article explores how physicians are helping patients living with atrial fibrillation address two health issues at the same time: irregular heart rhythms and stroke risk.

The CHAMPION-AF study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device as a first-line option for stroke risk reduction met all primary and secondary endpoints and demonstrated superior bleeding risk reduction and similar efficacy of the WATCHMAN FLX device compared to oral anticoagulants in a broad population of patients with non-valvular atrial fibrillation.

Learn how findings from the HI-PEITHO trial highlight a major advance in the treatment of immediate-risk pulmonary embolism, with ultrasound-assisted, catheter-directed thrombolysis using the EKOS™ Endovascular System reducing early complications without increasing major bleeding.

The VAPEUR clinical trial compared Rezūm™ Water Vapor Therapy to dual drug therapy for the treatment of symptomatic benign prostatic hyperplasia (BPH) in sexually active men. Key findings from the study demonstrate that Rezūm Therapy provides superior BPH symptom relief versus combination therapy while preserving sexual function.

Driven by an improved safety profile, strong patient demand and more predictable procedures, health systems are increasing investment in pulsed field ablation (PFA)—including technology like the FARAPULSE™ PFA Platform—to treat atrial fibrillation.

Read how Boston Scientific designed its latest employee campus with an intentional focus on collaboration for rapid innovation in this interview with Stephanie Board, group vice president, Research & Development, Interventional Cardiology & Vascular Therapies.

Learn how Boston Scientific consistently achieved superior results while minimizing distressing organizational transformations by creating and continually cultivating the business equivalent of a thriving, adaptive biological ecosystem.

Kyra Williams shares her experience with endoscopic sleeve gastroplasty, a minimally invasive weight loss procedure that helped support her goals.

AI adoption is much bigger than a workplace tech initiative – it’s a change management challenge. That’s why, writes SVP of enterprise services and digital officer Jodi Euerle Eddy, “if your IT department aims to create an AI-enabled workforce, a close IT and HR partnership is essential.”

Read how the AGENT™ Drug Coated Balloon — now available in the U.S. — addresses a critical unmet need for in-stent restenosis (ISR) treatment, using tech that represents a “quantum leap” forward.

A recent survey highlights that women are seeking new ways to lose weight, as Boston Scientific launches Endura Weight Loss Solutions to increase awareness of minimally invasive weight loss procedures.

Ronald Morton, M.D., chief medical officer, Urology, Boston Scientific sheds light on two taboo topics affecting millions of men: erectile dysfunction (ED) and stress urinary incontinence (SUI).

At STAT’s AI-focused Breakthrough Summit West, Ken Stein, MD, senior vice president and global chief medical officer, shares how artificial intelligence is helping cardiologists make the leap from available insights to actionable ones.

At DeviceTalks Minnesota, Ken Stein, MD, senior vice president and global chief medical officer, outlines the steps Boston Scientific takes to evaluate a market, choose a development approach and establish the groundwork for adoption.

CEO Mike Mahoney shares lessons learned over his career that helped him shape Boston Scientific's winning culture and drive the company’s growth.

Lisa Considine, senior vice president of global talent, describes the professional development opportunities offered by Boston Scientific to early career talent that supports the company’s top ranking on Forbes’ list of America’s Best Employers for New Grads.

Dr. Michael R. Jaff, chief medical officer, Peripheral Interventions, discusses new data supporting the Eluvia™ Drug-Eluting Vascular Stent System presented at the Charing Cross Symposium. The article also explores how design elements of the device contribute to long-term outcomes in treating peripheral artery disease and future opportunities for innovation in drug-device combination therapies.

Ken Stein, MD, senior vice president and global chief medical officer, highlights how AI is being applied today to deliver more proactive, personalized and precise medical

Jodi Eddy, chief information and digital officer, explains the importance of ensuring IT teams at rapidly growing organizations are at the table when key initiatives are being discussed.

Boston Scientific has approximately doubled its Minnesota workforce in the last 15 years. It has become the largest employer in both Maple Grove and Arden Hills. And it’s not done expanding.

Jodi Eddy, chief information and digital officer, unpacks three aspects of corporate culture that are separating leaders from the pack in the global pursuit of generative AI adoption.

Dr. Brad Sutton, chief medical officer, Atrial Fibrillation Solutions, discusses two of the latest FARAPULSE™ Pulsed Field Ablation System innovations and how the acquisition of Cortex, Inc. will fit into the Boston Scientific Electrophysiology portfolio.

In an interview with CNBC’s Jim Cramer, CEO Mike Mahoney shares how breakthrough products, an active venture portfolio and strategic acquisitions continue to drive high business performance.

Ken Stein, MD, senior vice president and global chief medical officer, discuss health inequities and Boston Scientific's work to improve access to care for underserved populations.

Boston Scientific presented a study at the 23rd American Society of Regional Anesthesia and Pain Medicine Meeting that demonstrates Fast-Acting Sub-Perception Therapy (FAST), with the WaveWriter spinal cord stimulation systems, as a breakthrough solution that significantly reduces chronic pain and improves patient outcomes with high satisfaction for up to 12 months, and no increase in opioid use during the primary endpoint interval.

Jodi Euerle Eddy, chief information and digital officer, shares the importance of interdepartmental collaboration in creating a culture of innovation that supports the investment, deployment and successful adoption of new technology.

As the number of people diagnosed with atrial fibrillation (AF) rises around the world, Ken Stein, MD, senior vice president and global chief medical officer and Nick Spadea-Annello, global president, Electrophysiology, along with industry experts, offer the Star Tribune perspective on the paradigm shift to pulsed field ablation for the treatment of AF, the explosive growth of the FARAPULSE™ Pulsed Field Ablation System, the competitive innovation race and the future of cardiac care.

Through interviews with senior executives and industry analysts, The Boston Globe explores how the combination of Boston Scientific’s acquisition strategy, in-house R&D and investment portfolio position the company for long-term success.

Boston Scientific has completed its $1.18 billion acquisition of Silk Road Medical, adding the TCAR stroke-prevention platform to its vascular portfolio to enhance patient outcomes and expand its minimally invasive treatment options.

Dr. Ken Stein, senior vice president and global chief medical officer, illustrates AI’s potential to enable more personalized care, especially through wearable devices and home-based health monitoring.

Camille Chang Gilmore, vice president of human resources and global chief diversity officer, shares our commitment to developing a workforce that is reflective of the patients and communities we serve, inclusive of individuals with disabilities.

Samir Bhattacharyya, vice president of global value and marketing for Health Economics & Market Access, Urology, discusses the impact erectile dysfunction (ED) can have on work productivity and mental health and the importance of ensuring ED treatment coverage is available to employees.

As the number of people living with conditions like prostate cancer or kidney stones increases, there is also a serious shortage of urologists to meet these growing patient needs. Senior vice president and president of Urology Meghan Scanlon discusses the importance of supporting the next generation of urologists to meet the evolving demands of this field.

Jodi Eddy, senior vice president and chief information and digital officer, shares how she transformed the IT organization and empowered her team to support the company’s strategic priorities.

The Boston Scientific Intracept™ Intraosseous Nerve Ablation System helps transform the lives of people who are living with chronic pain.

In an interview with CNBC’s Jim Cramer, CEO Mike Mahoney shares Boston Scientific’s strong track record of consistently delivering great results and what we’re looking forward to next.

Since 2008, Boston Scientific has worked closely with Boston Health Care for the Homeless Program to help close gaps in medical and social services for those living in shelters or on streets.

Dr. Ken Stein, SVP and chief global medical officer, discusses the tremendous opportunities to use digital capabilities in medtech.

Dr. Janar Sathananthan, chief medical officer, Interventional Cardiology Therapies, discusses a new treatment option in the U.S. for patients with coronary artery disease who experience in-stent restenosis.

Wendy Carruthers, executive vice president of human resources, describes hybrid work as the best of both worlds with benefits for employees and employers alike.

Boston Scientific announced that it has entered into a definitive agreement to acquire Silk Road Medical, Inc., a medical device company that has developed an innovative platform of products to prevent stroke in patients with carotid artery disease through a minimally invasive procedure called transcarotid artery revascularization (TCAR).

Boston Scientific announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRM™ System, the first modular cardiac rhythm management (CRM) system that consists of the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) System and the EMPOWER™ Leadless Pacemaker (LP).

A presentation from WIRED Health 2024 discusses how Boston Scientific is advancing technologies to transform chronic pain care today and in the future.

The first coronary drug-coated balloon to be FDA-approved in the U.S., the Boston Scientific AGENT^TM Drug-Coated Balloon addresses a clinical unmet need by treating and preventing reoccurrence of in-stent restenosis in patients with coronary artery disease.

Boston Scientific shares how real-world data can help optimize physician decision making when treating patients with pulmonary embolism (PE).

Lisa Considine, vice president of human resources, and Adriana Gonzalez, director of global supply chain, share how Boston Scientific’s on-site day care in Marlborough, MA provides support and flexibility for employees while reinforcing an organizational culture of caring.

Next generation spinal cord stimulation devices, including Boston Scientific’s WaveWriter Alpha^TM SCS System, are providing relief to people living with diabetic peripheral neuropathy who are unresponsive to drugs or experience side effects.

Dr. Brian Dunkin, chief medical officer, Endoscopy, and Mike Jones, SVP and president, Endoscopy, discuss how endoluminal surgery (ELS) products from the recent Apollo Endosurgery acquisition represent a step forward in gastrointestinal (GI) care.

If you’re looking to advance your career, Mary Beth Moynihan, senior vice president of market access and chief marketing officer, has three words for you: “You’re worth it.”

Boston Scientific’s market capitalization has grown nearly 10 times larger since Mike Mahoney joined as CEO in 2011. He shared key insights about corporate strategy at DeviceTalks Boston in May.

Eric Thépaut, executive vice president and president, Europe, Middle East and Africa, shares how digital education platforms, real-time and on-demand technologies and remote case support are being utilized to help patients.

Data supporting use of key Boston Scientific electrophysiology and cardiac rhythm management therapies, and the WATCHMAN FLX™ Left Atrial Appendage Closure Device were presented at Heart Rhythm 2023, the annual meeting of the Heart Rhythm Society.

Camille Chang Gilmore, vice president, human resources, and global chief diversity, equity & inclusion officer, shares what she believes are the core elements in a successful DEI initiative and why creating a workplace that encourages empathetic, collaborative engagement is critical for the innovation that powers the medical device industry.

Boston Scientific’s new global chief medical officer is already well-known in cardiovascular device space circles. Dr. Ken Stein joined Boston Scientific in 2009 as SVP and chief medical officer of its Rhythm Management business. He became chief medical officer for the entire company on Feb. 13.

Clinical trials are an early step in device and therapy development which have significant impact on the types of products available to patients. Boston Scientific leaders share how the company is working to advance diversity in medical research.

Trevor Boylston had transitioned from female to male a decade before he started working at Boston Scientific. He shares reflections on how navigating the world of work can be enormously challenging for members of the transgender community and how he got involved in the company’s LGBTQ resource group.

Boston Scientific introduced the first U.S. Food and Drug Administration (FDA)-cleared single-use duodenoscope in 2019. Therefore, it is fitting that our first conversation in the Industry Perspective section of iGIE is with Michael Jones, senior vice president and president, Endoscopy for Boston Scientific.

Jenny Dandin is an R&D engineer at Boston Scientific. In a recent telephone interview with Career Communications Group, she shared a unique perspective from her experience as a female making her way as an engineer at a top medical device company.

Paudie O’Connor, senior vice president of supply chain, shares lessons learned from the last few years of macro supply chain challenges, and why Boston Scientific puts its people at the center.

Medical technology company Boston Scientific is among the organizations working to reverse the under-representation of women and people of color specifically Black patients, in clinical trials. Its aptly named Close the Gap program aims to level the medical playing field.

Boston Scientific Corp. scaled back some shifts at its facilities in Puerto Rico in light of travel advisories, a spokeswoman said. But its sites remain fully functional and the company expects operations to resume at normal levels once the storm subsides and travel advisories are lifted.

Brad Sorenson, executive vice president, Global Operations, and Paudie O’Connor, senior vice president of supply chain, discuss how supply chain has evolved in recent years, including strategic supplier relationships, resilience and continuity planning and sustainability.

Boston Scientific has been named one of Fast Company's Best Workplaces for Innovators for the third consecutive year—this year earning a callout as a best workplace for women.

Gail Beauregard, vice president of global total rewards at Boston Scientific, discusses how the company strives to create an organization where employees feel that they belong and can do their best work.

Camille Chang Gilmore, vice president, human resources and global chief diversity, equity and inclusion officer at Boston Scientific shares how the company’s diversity and inclusion efforts are promoting equity with its caring culture.

How has Boston Scientific evolved over the last decade? What is the difference between a leader and a manager? What does it mean to prioritize innovation? Charmain and CEO Mike Mahoney answers these questions and more during a sit down with DeviceTalks.

Boston Scientific’s WATCHMAN FLX™ is associated with fewer major adverse events and higher rates of success than its predecessor, according to an analysis of registry data by researchers at Yale School of Medicine. The study looked at 27,000 recipients of Boston Scientific’s first-generation WATCHMAN 2.5, and the same number of recipients of its successor WATCHMAN FLX. The rate of major in-hospital adverse events was 1.35% in the FLX arm and 2.4% in the Watchman 2.5 cohort.

Using information from a number of continuous data-stream sensors in implantable cardiac devices, Boston Scientific developed the HeartLogic Heart Failure Diagnostic, which can predict heart failure events on average 34 days before they happen. The algorithm alerts doctors of worsening conditions, allowing for earlier intervention and preventative action.

Boston Scientific has put forward real-world safety data gathered on its left atrial appendage occlusion device, the WATCHMAN FLX™. The latest data from Boston Scientific, which spanned more than 16,000 patients with atrial fibrillation not caused by heart valve problems who received the next-generation WATCHMAN FLX device, demonstrated favorable outcomes.

The COVID-19 pandemic has exacerbated the opioid epidemic, and the need for a broader menu of non-opioid treatment options has never been greater. Boston Scientific continues to invest in cutting-edge therapies to help patients and their doctors navigate the ever-changing pain management journey. The Boston Scientific WaveWriter Alpha™ Spinal Cord Stimulation System provides multiple therapy options that can be used in combination to help patients find relief.

Boston Scientific has spent approximately $1 billion buying stakes in about 50 companies globally through its ventures portfolio as a source for new innovation and potential mergers and acquisitions down the road. Since 2018, half of the 16 acquisitions the company completed went through Boston Scientific Ventures, including three of five acquisition targets in 2021.

Baptist Health cardiologist Salil Patel has performed the first procedure in Northeast Florida using the SYNERGY MEGATRON™ stent during a coronary procedure to eliminate blockages in a patient’s heart. The SYNERGY MEGATRON™ is designed for use in large proximal vessels and features architecture with increased strength as well as the ability to expand to 6.0mm in diameter and accommodate tapered vessels.

Mitchell Salloum became the first patient to receive a WATCHMAN™ implant in Wyoming. The Boston Scientific WATCHMAN implant is placed into a patient’s heart in a one-time procedure that may reduce stroke risk for a lifetime in patients with irregular heartbeats.

Many Fortune 500 companies have long-standing, well-oiled programs that often funnel into post-grad development and leadership programs or full-time jobs. For Lauren Nakamura, her marketing internship at Boston Scientific changed the course of her career and gave her confidence and reassurance that she was joining a workplace culture that prioritized work-life integration.

The MODULAR ATP clinical trial has begun to enroll patients to evaluate the safety, performance and effectiveness of Boston Scientific’s mCRM modular therapy system, which includes the Emblem MRI S-ICD and the Empower MPS leadless pacemaker.

*The EMPOWER MPS is an investigational device and limited by U.S. law to investigational use only. It is not available for sale. Some device references are for informational purposes only and are pending CE Mark. Not available in the European Economic Area.

The global medical device manufacturer has maintained operational continuity throughout the pandemic, using clear processes and procedures mixed with a healthy dose of care.

Our innovative TheraSphere™ technology, which increases HCC liver cancer survival rates, may be an effective treatment for other tumors.

CIO and SVP of IT Jodi Euerle Eddy, recently named one of FiercePharma’s 2021 Fiercest Women in Life Sciences, reflects on her career and the opportunity to turn Boston Scientific’s digital transformation strategy into a competitive advantage.

Our CHAMPION AF clinical trial is studying whether the WATCHMAN FLX device can reduce the risk of stroke for more people suffering from AFib. Learn more about one patient enrolled in the trial in Sydney, Australia.

How Boston Scientific built a corporate culture of diversity and equity that encourages collaboration and innovation.

New high-resolution imaging solutions from Boston Scientific are designed to provide a clearer view of the human anatomy

In the race to secure computer chips amid a global shortage, medical device makers say they have found their ace card: their products save lives. Brad Sorenson, senior vice president, Global Supply Chain, shares how the company's' relationship with suppliers has helped Boston Scientific secure supply as typical lead times for components quintupled from three to 15 months.

Jodi Eddy, chief information and digital officer at Boston Scientific, explains the link between broadband access and telehealth access—and the subsequent impact on healthcare disparities.

Boston Scientific’s tumor-targeting glass microbeads continue to shatter expectations for cancer treatment. The latest results of a long-term study showed adding TheraSpheres to a standard chemotherapy regimen could extend survival for patients with colorectal cancer that has spread to the liver.

CAUTION: In the U.S., the use of TheraSphere for mCRC is for investigational use only as the safety and effectiveness have not been established.

As the University of Minnesota launches the Center for Medical Device Cybersecurity, KSTP reports how Boston Scientific is one of five Minnesota device companies that have provided funding.

Boston Scientific Chief Digital Health Officer David Feygin shares his career journey and leadership tips with professionals on the Ivy Podcast.

Boston Scientific recently announced FDA clearance of the EXALT Model B single-use bronchoscope, intended for bedside procedures in intensive care units or in the operating room. Medgadget had the opportunity to speak with Dave Pierce, Executive Vice President and President, MedSurg and President, Endoscopy, at Boston Scientific, about the new bronchoscope.

BostonScientific MedSurg EVP Dave Pierce shares his excitement for the future of our Endoscopy and Urology/Pelvic Health businesses, and why he’s proud of how the company has navigated through the uncertainty of the past year.

Boston Scientific has won FDA 510(k) clearance for a single-use bronchoscope designed to eliminate the infection risk associated with reusable devices.

Opinion: Boston Scientific's president of endoscopy writes that government policies have enabled the medtech giant to reinvest profits in multiple areas of innovation. "Patients cannot benefit from bets we don’t make.

A new study using Boston Scientific's EkoSonic endovascular system (EKOS) aims to address current gaps in clinical guidelines for the treatment of pulmonary embolism.

The advent of cardiac resynchronization therapy (CRT) changed the landscape of heart failure management options, but perhaps a third of patients receiving biventricular pacemakers for CRT don't respond to it. The observational study, SMART MSP, demonstrated that CRT with multisite LV pacing (MSP) made responders out of half of patients in whom CRT had failed over the previous 6 months in a prospective trial.

CMS granted a NTAP for single-use duodenoscopes, which applies to Boston Scientific's Exalt Model D single-use duodenoscope, as part of the FY 2022 hospital IPPS. This means that beginning Oct. 1, 2021, CMS will give hospitals additional device reimbursement when single-use duodenoscopes are used for eligible cases in the hospital inpatient setting.

David Knapp, Vice President of Research and Development for Peripheral Interventions at Boston Scientific, joins us to talk about the value of innovation culture, how businesses today go about creating and sustaining an innovative company and embracing the sustainability imperative.

Fueled by billions of its own dollars, the medical technology industry's successes are built on a willingness to invest with a long-term horizon. Some of our bets may never pay off, but our successes have the potential to transform millions of lives.

Boston Scientific has exerted its right to acquire the remaining shares of Farapulse, a company that has developed a pulsed field ablation system for the treatment of cardiac arrhythmias.

Vance Brown has worked in the company's legal department for 20 years. But he's facing new challenges as the GC, including the task of bringing a global workforce back to the office.